The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.

Anthropic released Claude Fable 5, a Mythos-class model with conservative safeguards that excels at long-context reasoning, software engineering, vision, knowledge work, and life-science research. A restricted-lifted variant, Claude Mythos 5, is available to vetted cyberdefense partners under Project Glasswing. Both are priced at $10 per million input tokens and $50 per million output tokens and lead benchmarks across multiple domains.

This post lists nine key quotes from a San Francisco talk by Demis Hassabis and Sebastian Mallaby covering everything from OpenAI’s 50% bankruptcy risk to the need for new “AlphaFold” moments in drug discovery. They debate AGI probabilities, frontier cyber defense access, global AI optimism, and the economic and philosophical challenges of a post-scarcity future.

OpenAI trained a new LLM, GPT-Rosalind, on 50 common biological workflows and major public databases to help researchers navigate massive genomic and protein datasets. The model links genotype to phenotype, suggests biological pathways, and prioritizes potential drug targets by leveraging mechanistic understanding.

AWS introduced Amazon Bio Discovery, an AI-driven platform that lets researchers run complex drug-design workflows without coding. It provides a library of biological foundation models, an AI agent for workflow setup and analysis, and links to lab partners for synthesis and testing, cutting months of work down to weeks.

AI model costs and rapid obsolescence are eating into margins—each new generation demands more compute, serves less time, and recoups less revenue. The only way to capture lasting value is by using closed-door models to drive high-value discoveries (like drug design) and own the instruments that generate proprietary data.